- Home
- Products
- Customized FluoroAb™
- CEACAM1
- Anti-CEACAM1 MAb (Clone 1)-iFluor® 350 Succinimidyl Ester
Anti-CEACAM1 MAb (Clone 1)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS191)
This product is comprised of an Humanized Anti-CEACAM1 IgG1-Fab' fragment (Clone 1) labeled with iFluor® 350 Succinimidyl Ester. iFluor® 350 Succinimidyl Ester is a Blue-fluorescent dye and it's excitation/emission is 345/450 nm.
- TARGET
- ANTIBODY
- DYE
- Name
- CEACAM1
- Alternative Names
- CEACAM1; carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein); BGP; carcinoembryonic antigen-related cell adhesion molecule 1; BGP1; CD66a; antigen CD66; CD66a antigen; BGPI;
- Overview
- This gene encodes a member of the carcinoembryonic antigen (CEA) gene family, which belongs to the immunoglobulin superfamily. Two subgroups of the CEA family, the CEA cell adhesion molecules and the pregnancy-specific glycoproteins, are located within a 1.2 Mb cluster on the long arm of chromosome 19. Eleven pseudogenes of the CEA cell adhesion molecule subgroup are also found in the cluster. The encoded protein was originally described in bile ducts of liver as biliary glycoprotein. Subsequently, it was found to be a cell-cell adhesion molecule detected on leukocytes, epithelia, and endothelia. The encoded protein mediates cell adhesion via homophilic as well as heterophilic binding to other proteins of the subgroup. Multiple cellular activities have been attributed to the encoded protein, including roles in the differentiation and arrangement of tissue three-dimensional structure, angiogenesis, apoptosis, tumor suppression, metastasis, and the modulation of innate and adaptive immune responses. Multiple transcript variants encoding different isoforms have been reported, but the full-length nature of all variants has not been defined.
- Overview
- Humanized Anti-CEACAM1 IgG1-Fab’ fragment (Clone 1)
- Species Reactivity
- Human
- Name
- iFluor® 350 Succinimidyl Ester
- Color
- Blue
- Excitation⁄Emission (nm)
- 345/450
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS191. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-966 | Anti-CEACAM1 (Arcitumomab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-967 | Anti-CEACAM1 (Arcitumomab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
| ADC-W-963 | Anti-CEACAM1 (Arcitumomab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-965 | Anti-CEACAM1 (Arcitumomab)-MC-Vc-PAB-MMAE ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | MMAE |
| ADC-W-964 | Anti-CEACAM1 (Arcitumomab)-MC-MMAF ADC | MC (maleimidocaproyl) | MMAF |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-OxLDL MAb (Clone 2)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS6206)
- Anti-IL23A MAb (Clone 6)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS15175)
- Anti-FOLR1 MAb (Clone 7)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11766)
- Anti-CD19 MAb (Clone 31)-iFluor® 460 Succinimidyl Ester (CAT#: WJY0-LS8627)
- Anti-F3 MAb (Clone 4)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS1787)
- Anti-C. albicans Hsp90 MAb (Clone 1)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5370)
- Anti-MS4A1 MAb (Clone 26)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3974)
- Anti-CD28 MAb (Clone 1)-iFluor® 546 Succinimidyl Ester (CAT#: WJY0-LS14615)
- Anti-PDCD1 MAb (Clone 12)-iFluor® 488 Succinimidyl Ester (CAT#: WJY0-LS10687)
- Anti-NGF MAb (Clone 2)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS12980)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.
